Maci

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

avtologni kultivirani hondrociti

Available from:

Vericel Denmark ApS

ATC code:

M09AX02

INN (International Name):

matrix-applied characterised autologous cultured chondrocytes

Therapeutic group:

Druga zdravila za motnje mišično-skeletnega sistema

Therapeutic area:

Zlomi, hrustanec

Therapeutic indications:

Popravljanje simptomatskih okvar hrustanca kolena.

Product summary:

Revision: 4

Authorization status:

Umaknjeno

Authorization date:

2013-06-27

Patient Information leaflet

                                18
9.
POSEB
NA NAVODILA ZA SHRANJEVANJE
Ne shranjujte v hladilniku ali zamrzujte. Do začetka uporabe
shranjujte v zunanji ovojnini pri
temperaturi do 37 °C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Razlit a
li odpadni material odstranite kot kirurški odpadni material v skladu
z lokalno prakso.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Vericel Denmark ApS
Amaliegade 10
DK-1256 Kopenhagen K
Danska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/13/847
/001
13.
ŠTEVILKA SERIJE, ENOTNE OZNAKE DAROVANJA IN IZDELKOV
Serija: {številka serije}
Biopsija št.: {številka biopsije}
14.
NAČIN IZDAJANJA ZDRAVILA
Predpi
sovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprej
eta je utemeljitev, da Braillova pisava ni potrebna
_ _
Zdravilo nima več dovoljenja za promet
19
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
POSODICA
1.
IME ZDRAVILA IN POT(I) UPORABE
MACI 500.000–1.000.000 celic/cm
2
matriks za implantacijo
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
4.
ŠTEVILKA SERIJE
Serija: {številka serije}
Bolnik: (ime – datum rojstva {DD mmm LLLL})
Biopsija št.: {številka biopsije}
Matriks: 1/1
Matriks: 1/2
Matriks: 2/2
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
1 matriks za implamtacijo.
6.
DRUGI PODATKI
Samo za avtologno uporabo.
Zdravilo nima več dovoljenja za promet
20
B. NAVODILO ZA UPORABO
Zdravilo nima več dovoljenja za promet
21
NAVODILO ZA UPORABO
MACI 500.000 DO 1.000.000 CELIC/CM
2 MATRIKS ZA IMPLANTACIJO
na matriks nanešeni karakterizirani avtologni gojeni hondrociti
Za
t o
zd r a vi l o
s e
i zva j a
d o d a t no
s p re ml j a nj e
va r n o s ti .
T a ko
b o d o
h i t rej e
n a
vo l j o
n o ve
informacije o njegovi varnosti. Tudi sami lahko k temu prispevate
tako, da poročate o katerem
koli neželenem učinku zdravila, ki bi se utegnil pojaviti pri vas.
Glejte na koncu poglavja
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima več dovoljenja za promet
2
Za to zdravilo se izvaja dodatno spremljanje varnosti. Tako bodo
hitreje na voljo nove informacije
o njegovi varnosti. Zdravstvene delavce naprošamo, da poročajo o
katerem koli domnevnem
neželenem učinku zdravila. Glejte poglavje 4.8, kako poročati o
neželenih učinkih.
1.
IME ZDRAVILA
MACI 500.000 do 1.000.000 celic/cm
2
matriks za implantacijo
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsak vsadek vsebuje na matriks nanesene karakterizirane avtologne
gojene hondrocite.
2.1
SPLOŠEN OPIS
Karakterizirani viabilni avtologni hondrociti, ekspandirani _ex vivo_,
ki izražajo hondrocitsko specifične
markerske gene, nacepljeni na kolagensko membrano tipa I/III,
pridobljeno iz prašiča, z oznako CE.
2.2
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsak matriks za implantant sestavljajo karakterizirani avtologni
hondrociti na 14,5 cm² kolagenske
membrane tipa I/III, z gostoto 500.000 do 1.000.000 celic na cm
2
, kirurg ga obreže glede na velikost
in obliko bolnikove okvare.
_ _
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Matriks za vsaditev.
Vsadek je neprozorna, belkasta membrana, nacepljena s hondrociti, na
voljo v 18-mililitrski
brezbarvni raztopini v posodici.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo MACI je indicirano za popravljanje simptomatskih okvar
kolenskega hrustanca po vsej
debelini (III. in IV. stopnje Modificirane lestvice Outerbridge, angl.
_Modified Outerbridge Scale)_ v
obsegu 3–20 cm
2
pri odraslih bolnikih z zrelim okostjem.
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravilo MACI je namenjeno samo za avtologno uporabo.
Zdravilo MACI mora vsaditi kirurg, ki je posebej izurjen in
usposobljen za uporabo zdravila MACI.
Odmerjanje
Količina uporabljenega zdravila MACI je odvisna od velikosti
(površina v cm
2
) okvare hrustanca.
Kirurg obreže matriks za vsaditev na velikost in obliko okvare, pri
čemer zagotovi, da je poškodovani
predel v celoti prekrit in da je stran z vsajeni
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-07-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-07-2018
Public Assessment Report Public Assessment Report Bulgarian 05-07-2018
Patient Information leaflet Patient Information leaflet Spanish 05-07-2018
Public Assessment Report Public Assessment Report Spanish 05-07-2018
Patient Information leaflet Patient Information leaflet Czech 05-07-2018
Public Assessment Report Public Assessment Report Czech 05-07-2018
Patient Information leaflet Patient Information leaflet Danish 05-07-2018
Public Assessment Report Public Assessment Report Danish 05-07-2018
Patient Information leaflet Patient Information leaflet German 05-07-2018
Public Assessment Report Public Assessment Report German 05-07-2018
Patient Information leaflet Patient Information leaflet Estonian 05-07-2018
Public Assessment Report Public Assessment Report Estonian 05-07-2018
Patient Information leaflet Patient Information leaflet Greek 05-07-2018
Public Assessment Report Public Assessment Report Greek 05-07-2018
Patient Information leaflet Patient Information leaflet English 05-07-2018
Public Assessment Report Public Assessment Report English 05-07-2018
Patient Information leaflet Patient Information leaflet French 05-07-2018
Public Assessment Report Public Assessment Report French 05-07-2018
Patient Information leaflet Patient Information leaflet Italian 05-07-2018
Public Assessment Report Public Assessment Report Italian 05-07-2018
Patient Information leaflet Patient Information leaflet Latvian 05-07-2018
Public Assessment Report Public Assessment Report Latvian 05-07-2018
Patient Information leaflet Patient Information leaflet Lithuanian 05-07-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-07-2018
Public Assessment Report Public Assessment Report Lithuanian 05-07-2018
Patient Information leaflet Patient Information leaflet Hungarian 05-07-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 05-07-2018
Public Assessment Report Public Assessment Report Hungarian 05-07-2018
Patient Information leaflet Patient Information leaflet Maltese 05-07-2018
Public Assessment Report Public Assessment Report Maltese 05-07-2018
Patient Information leaflet Patient Information leaflet Dutch 05-07-2018
Public Assessment Report Public Assessment Report Dutch 05-07-2018
Patient Information leaflet Patient Information leaflet Polish 05-07-2018
Public Assessment Report Public Assessment Report Polish 05-07-2018
Patient Information leaflet Patient Information leaflet Portuguese 05-07-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 05-07-2018
Public Assessment Report Public Assessment Report Portuguese 05-07-2018
Patient Information leaflet Patient Information leaflet Romanian 05-07-2018
Public Assessment Report Public Assessment Report Romanian 05-07-2018
Patient Information leaflet Patient Information leaflet Slovak 05-07-2018
Public Assessment Report Public Assessment Report Slovak 05-07-2018
Patient Information leaflet Patient Information leaflet Finnish 05-07-2018
Public Assessment Report Public Assessment Report Finnish 05-07-2018
Patient Information leaflet Patient Information leaflet Swedish 05-07-2018
Public Assessment Report Public Assessment Report Swedish 05-07-2018
Patient Information leaflet Patient Information leaflet Norwegian 05-07-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 05-07-2018
Patient Information leaflet Patient Information leaflet Icelandic 05-07-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 05-07-2018
Patient Information leaflet Patient Information leaflet Croatian 05-07-2018
Public Assessment Report Public Assessment Report Croatian 05-07-2018

View documents history